[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353814-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353814-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-slc6a8-suppresses-tumor-growth-and-enhances-ferroptosis-in-hepatocellular-carcinoma","Targeting SLC6A8 suppresses tumor growth and enhances ferroptosis in hepatocellular carcinoma","","Hepatocellular carcinoma remains a therapeutic challenge due to limited treatment options and insufficient biomarkers, while the creatine transporter SLC6A8 has been implicated in multiple cancers. This study examines SLC6A8 expression in HCC and evaluates whether it can serve as a therapeutic target. SLC6A8 was assessed using bioinformatics, qPCR, and immunohistochemistry, with functional testing in vitro and in vivo. Genetic silencing or pharmacologic blockade of SLC6A8 suppressed tumor growth and increased ferroptosis susceptibility, potentiating the ferroptosis inducer RSL3 in xenograft models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-slc6a8-suppresses-tumor-growth-and-enhances-ferroptosis-in-hepatocellular-carcinoma/353814/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-slc6a8-suppresses-tumor-growth-and-enhances-ferroptosis-in-hepatocellular-carcinoma/353814.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study?","Question",{"text":63,"@type":64},"To determine the role of SLC6A8 in hepatocellular carcinoma (HCC) and assess its suitability as a therapeutic target, including evaluating synergy with ferroptosis induction.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was SLC6A8 evaluated and what were its key findings?",{"text":68,"@type":64},"SLC6A8 expression and clinical relevance were assessed using bioinformatics, qPCR, and immunohistochemistry. SLC6A8 was upregulated in HCC tissues and linked to poor prognosis, and its knockdown reduced HCC cell proliferation and migration.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the relationship between SLC6A8 inhibition and ferroptosis in this work?",{"text":72,"@type":64},"Inhibiting SLC6A8 increased HCC cells’ susceptibility to ferroptosis and significantly enhanced the anti-tumor efficacy of the ferroptosis inducer RSL3 in xenograft models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353814,1790197708,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Journal of Cancer Research and Clinical Oncology (2026) 152:59  \n[https://doi.org/10.1007/s00432-026-06442-8](https://doi.org/10.1007/s00432-026-06442-8)  \nRESEARCH  \nTargeting SLC6A8 suppresses tumor growth and enhances ferroptosisin hepatocellular carcinoma  \nWenfang Bao1 · Yang Yu1 · Guofeng Yu2 · Jingde Chen1 · Yandong Li1 · Yanan Hai1  \nReceived: 29 September 2025 / Accepted: 14 February 2026 © The Author(s) 2026  \nAbstract  \nBackground Hepatocellular carcinoma (HCC) persists as a therapeutic challenge owing to restricted treatment alternativesand the dearth of effective biomarkers. The creatine transporter SLC6A8 has been documented to participate in the progression of various malignancies. However, the role that SLC6A8 plays in HCC remains poorly characterized. Hence, this study aimed to investigate the function of the SLC6A8 in HCC and evaluate its candidacy as a therapeutic target.  \nMethods Bioinformatics analysis, qPCR on tissue specimens, and immunohistochemistry on tissue microarrays were utilized to assess the expression and clinical significance of SLC6A8 in HCC. In vitro assays including cell viability, colony formation, and cell migration, as well as an in vivo subcutaneous xenograft model, were employed to explore the impacts of both genetic silencing of SLC6A8 and pharmacological blockade of SLC6A8 on HCC tumor growth. The anti-tumor effect of SLC6A8 inhibition in combination with the ferroptosis inducer RSL3 in HCC was also examined in cellular and animal models.  \nResults Our findings revealed that SLC6A8 is notably upregulated in HCC tissues and is associated with a poor prognosis. SLC6A8 knockdown suppressed cell proliferation and migration of HCC cells. RGX-202 also demonstrated potent antitumor efficacy in HCC cells both in vitro and in vivo. Moreover, SLC6A8 inhibition augmented cellular susceptibility to ferroptosis and significantly enhanced the anti-tumor efficacy of the ferroptosis inducer RSL3 in xenograft models of HCC. Conclusion These findings underscore SLC6A8 as a promising therapeutic target, and its inhibitor combined with ferroptosis inducers may serve as an innovative treatment strategy for improving the therapeutic effect in HCC.  \nKeywords SLC6A8 · Hepatocellular carcinoma · RGX-202 · Ferroptosis  \nIntroduction  \nLiver cancer ranks as the sixth most frequently diagnosed cancer, with an estimated 865,000 new cases each year. It also stands as the third leading cause of cancer-related mortality, resulting in over 750,000 deaths worldwide (Bray et al. 2024) . The main types of primary liver cancer  \nWenfang Bao, Yang Yu and Guofeng Yu contributed equally to this work.  \n􀀍 Yanan Hai [2205696@tongji.edu.cn](2205696@tongji.edu.cn)  \n1 Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 150 Ji-Mo Rd, Shanghai 200120, China  \n2 Department of Oncology, Ji’an Central People’s Hospital, Ji’an 343000, China  \nare hepatocellular carcinoma (HCC), which accounts for 75%-85%, and intrahepatic cholangiocarcinoma (ICC), comprising 10%-15% . Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) is responsible for 21%-55% of HCC cases globally (Rumgay et al. 2022) . The mainstay treatment options for advanced HCC encompass tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and combination with or without anti-vascular endothelial growth factor (VEGF) therapy (Zheng et al. 2025) . The distinct characteristics and a lack of definitive biomarkers of HCC constrain the efficacy of current therapies, urgently driving the request for novel therapeutic modalities and predictive biomarkers.  \nSolute carrier family 6 member 8 (SLC6A8), also known as “CT1” or “CRTR”, mapped to Xq28, is a creatine transporter (Salomons et al. 2001) . SLC6A8 enables cells to import phosphocreatine, which functions as a swiftly mobilizable energy reserve for adenosine triphosphate  \n1 3  \n(ATP) regeneration, in a Na+/Cl-dependent manner (Stary and Bajda 2023) .","cbCaipLxGpkmK6dV","https://ap.wps.com/l/cbCaipLxGpkmK6dV","pdf",5501312,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion\n# Keywords\n# Introduction\n# Materials and methods","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"To determine the role of SLC6A8 in hepatocellular carcinoma (HCC) and assess its suitability as a therapeutic target, including evaluating synergy with ferroptosis induction.\"},{\"question\":\"How was SLC6A8 evaluated and what were its key findings?\",\"answer\":\"SLC6A8 expression and clinical relevance were assessed using bioinformatics, qPCR, and immunohistochemistry. SLC6A8 was upregulated in HCC tissues and linked to poor prognosis, and its knockdown reduced HCC cell proliferation and migration.\"},{\"question\":\"What is the relationship between SLC6A8 inhibition and ferroptosis in this work?\",\"answer\":\"Inhibiting SLC6A8 increased HCC cells’ susceptibility to ferroptosis and significantly enhanced the anti-tumor efficacy of the ferroptosis inducer RSL3 in xenograft models.\"}]","Targeting SLC6A8 suppresses tumor growth and enhances ferroptosis in hepatocellular carcinoma | PDF",1790107387,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6a66ac85030723ea59463a623305efa.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4232c688ea77575a981b780f3ee3df5.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e96e22b624ea9453d285a9b4d4ccfb91.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/090f0c4fda67d7598288cce4fffba230.webp",980,1301]